Electrophysiological Registry Duesseldorf

Registry on Electrophysiological Studies (EPS) at University Hospital Düsseldorf

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07196176

Enrollment

1000

Registered

2025-09-29

Start date

2019-06-01

Completion date

2031-12-31

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardias, Ventricular Tachycardia (VT)

Keywords

atrial fibrillation, catheter ablation, cardioversion

Brief summary

This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.

Detailed description

This is a single-center observational registry including all patients treated with EPS, catheter ablation, or electrical cardioversion at the Department of Cardiology, Pneumology, and Angiology, University Hospital Düsseldorf. Retrospective data from 2011 onward and prospective data from 2015 onward are collected. The registry systematically records demographic data, comorbidities, laboratory and imaging results, procedural details, and follow-up outcomes. Patients are routinely followed at 1, 3, 6, 12, and 24 months after the procedure. Additional follow-up may be performed by telephone interview with patients or referring physicians to improve data quality. Primary endpoints focus on safety (peri- and postprocedural complications, late adverse events) and efficacy (recurrence of arrhythmias, need for repeat procedures, pacemaker implantation, or new medications). Secondary endpoints include hospitalization and all-cause mortality. Participation does not alter routine diagnostic or therapeutic decisions, and no additional invasive procedures are performed. Data will be used for quality assurance and to improve understanding of prognostic factors, with the ultimate aim of optimizing future patient care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who undergo an electrophysiological study (EPS) or electrical cardioversion at University Hospital Düsseldorf since 2015 (retrospective cohort) * Patients scheduled to undergo an EPS or electrical cardioversion at University Hospital Düsseldorf from 2019 onward (prospective cohort) •- Written informed consent for participation in the registry (prospective part only)

Exclusion criteria

* \< 18 years * Lack of written informed consent * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Periprocedural and postprocedural safety events	Up to 24 months after procedure	All cardiovascular adverse events or complications occurring during hospitalization and late complications after discharge related to EPS, ablation, or electrical cardioversion.
Clinical efficacy outcomes	Up to 24 months after procedure	Procedural success, recurrence of arrhythmias or symptoms, and need for repeat EPS/cardioversion, additional medication, or device implantation (e.g., pacemaker).

Secondary

Measure	Time frame	Description
All-cause mortality	Up to 24 months after procedure	Death from any cause during follow-up.
All-cause hospitalization	Up to 24 months after procedure	Any hospital admission for cardiovascular or non-cardiovascular reasons during follow-up

Countries

Germany

Contacts

Primary ContactObaida Rana, MD

obaida.rana@med.uni-duesseldorf.de+492118118800

Backup ContactLisa Dannenberg, MD

LisaKristina.Dannenberg@med.uni-duesseldorf.de+ 49211 81 05315

Outcome results